Feasibility Test of Folic Acid on Acute Kidney Injury

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

September 30, 2027

Conditions
Acute Kidney Injury
Interventions
DRUG

Folic Acid 5 MG

In this study, oral folic acid at 5 mg/d (\~83.3 μg/kg) is chosen. In a rat model of AKI with ischaemia-reperfusion, intraperitoneal injection of 5-methyltetrahydrofolate (5-MTHF) at 3 μg/kg body weight twice (30 min before ischaemia and 3 h after reperfusion) improved kidney function and alleviated oxidative stress within 24 hours. The average body weight is around 60 kg for Chinese. Considering the oral route often requires larger doses than injection to produce the same effect, oral folic acid at 5 mg/d (\~83.3 μg/kg) is chosen to test its effect on AKI. Depending on the clinical condition, the therapeutic dose of folic acid varies. For foetal support during pregnancy, daily doses of 1 mg of folic acid are recommended; for lowering homocysteine, up to 5 mg daily are generally used.

Trial Locations (1)

Unknown

Queen Mary Hospital, Hong Kong

All Listed Sponsors
collaborator

Queen Mary Hospital, Hong Kong

OTHER

lead

The University of Hong Kong

OTHER